Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.

ABSTRACT:

Objective

To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers.

Research design and methods

Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.

Results

Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. The

SUBMITTER: Bunck MC 

PROVIDER: S-EPMC2909051 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature